Research Tool
Genetically coded FRET-based biosensor of MMP-9 activity and its application
Patent inventors: Michał Stawarski, Jakub Włodarczyk, Leszek Kaczmarek

The present invention relates to a genetically encoded FRET-based biosensor to monitor the activity of matrix metalloproteinase 9 (MMP-9). MMP-9 is an extracellular acting endopeptidase implicated in both physiological and pathological processes. A genetically encoded FRET biosensor anchored in the cellular membrane allows studying the proteolytic activity of MMP-9 with high spatiotemporal resolution at the exact region of MMP-9 action on the cell. Applicability of the biosensor, both in vitro and in vivo in living cells, has been demonstrated by ratiometric analysis of cleavage of the biosensor by a purified auto-activating mutant of MMP-9.

Patent was granted in USA and Nencki Institute is the sole applicant.

For more information contact Technology Transfer Office.

Application number:
P.405046 (12 Aug 2013), PCT/IB2014/063883 (12 Aug 2014), CN201480047715.0 (12 Aug 2014), EP 20140789607 (12 Aug 2014), JP 2016-533982 (12 Aug 2014), US 14911821 (12 Aug 2014)
Patent number:
US 9914955 (13 Mar 2018)
Patent status: